Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors.
When antagonist-occupied steroid receptors have agonist-like effects, the clinical consequences are grave. We present evidence that human progesterone B-receptors (hPRB) when occupied by progesterone antagonists, inappropriately activate transcription by an unusual mechanism that does not require the canonical progesterone response element (PRE). In HeLa cells cotransfected with a PRE-tk-chloramphenicol acetyltransferase reporter and a hPRB expression vector, strong transcription is seen not only when receptors are activated by the agonist R5020, but also in the presence of the three antiprogestins, RU486, ZK112993, and ZK98299. Human PRB occupied by ZK98299 do not bind to a PRE, suggesting that the transcriptional stimulation is independent of DNA binding. Indeed, a tk-chloramphenicol acetyltransferase promoter-reporter lacking the PRE loses transcriptional activation by the agonist, but retains transactivation by the three antagonists. The PRE-independent antagonist-induced transcription requires that hPRB have an intact DNA-binding domain, but hPR target gene specificity is not required, because a hPRB mutant that binds an estrogen response element still activates transcription. It appears that antagonist-occupied hPR activate transcription without binding to a PRE, perhaps by interacting with tethering proteins instead. Even a gene that is not a normal progesterone target could be aberrantly activated. Human cells contain equimolar amounts of hPRB and the N-terminally truncated natural isotype, hPRA. Unlike hPRB, hPRA are not transcriptionally activated by progesterone antagonists. We, therefore, tested the effects of antagonists when the two receptor isotypes are coexpressed and found that A-receptors can annul the inappropriate transcription by B-receptors. Thus, when both receptor forms are present, the hPRA phenotype is dominant. Moreover, pure hPRB/hPRA heterodimers, produced by fos/jun leucine zipper domain-hPR chimeras, also have the inactive transcriptional phenotype of hPRA. Our studies suggest not only that the two hPR isotypes are functionally quite different, but also that some of the agonist-like transcriptional effects of antagonist-occupied B-receptors proceed through novel mechanisms.
Tung
L
L
Department of Medicine, University of Colorado Health Sciences Center Denver 80262.
Mohamed
M K
MK
Hoeffler
J P
JP
Takimoto
G S
GS
Horwitz
K B
KB
D001665:Binding Sites; D004247:DNA / Q000378:metabolism*; D017930:Genes, Reporter; D016762:Genes, fos; D016758:Genes, jun; D006067:Gonanes / Q000494:pharmacology; D006367:HeLa Cells; D006801:Humans; D016350:Leucine Zippers; D015735:Mifepristone / Q000031:analogs & derivatives / Q000494:pharmacology; D010641:Phenotype; D011374:Progesterone / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D011401:Promoter Regions, Genetic; D011980:Receptors, Progesterone / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D011993:Recombinant Fusion Proteins; D014158:Transcription, Genetic; D014162:Transfection
D006067:Gonanes; D011980:Receptors, Progesterone; D011993:Recombinant Fusion Proteins; C064879:ZK 112993; D015735:Mifepristone; D011374:Progesterone; D004247:DNA; C053238:onapristone